CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 7 enrolled
Drug / intervention
Sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03933904
NCT03933904Phase 2Active
CompareCT.gov

A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

University of Pennsylvania·interventional·Posted May 1, 2019·Updated Mar 3, 2026

In Brief

A Phase 2 clinical trial evaluating Sirolimus for Castleman Disease and Castleman's Disease, Multicentric. Active but no longer recruiting, targeting 7 participants across 2 sites.

Detailed Summary

The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastleman Disease, Castleman's Disease, Multicentric
CountriesUnited States
Collaborators--

Timeline

Phase 2ActiveOverdue
2020202120222023202420252026
First PostedMay 1, 2019
Enrollment StartSep 25, 2019
Primary CompletionJun 30, 2024
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.2 years ago

Interventions

Sirolimusdrug

Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.